Alzheimer’s is a devastating type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly in the sixth to eighth decade, and get worse over time, becoming severe enough to interfere with daily tasks. As our population ages, effective treatments to slow down and even reverse Alzheimer’s are desperately needed. At New England Institute for Clinical Research, we currently are working on just that.
Abbvie M23-515
This study is designed to evaluate the safety and efficacy of ABBV-552 for the symptomatic
treatment of early Alzheimer’s Disease (AD) in people 50-90 years of age. ABBV-552 is a
unique medication that acts to increase communication between neurons in order to
protect them from dying, which is thought to combat the brain degeneration seen in AD and slow the resulting cognitive decline. The study is approximately 20 weeks in total duration, including a 12-week treatment period. During the treatment period, eligible patients will be randomized to receive either one of three doses of the study medication or placebo and will take their assigned medication by mouth once daily for 12 weeks. This study is aimed at expanding the limited options for treatment of the cognitive symptoms of Alzheimer’s Disease.
Learn more: https://clinicaltrials.gov/study/NCT05771428
Suven CTP3S1502HT6
The objective of this study is to evaluate the efficacy, safety, tolerability, and
pharmacokinetics of Masupirdine for the treatment of agitation associated with
Alzheimer’s Disease. Masupirdine works by modulating chemicals in the brain, like
dopamine, serotonin, and norepinephrine, that are associated with mood, behavior, and
aggression. The participant will be randomized to receive either the study medication daily
in the form of a tablet or a matching placebo for 12 weeks following a 2–4-week screening
period to confirm eligibility.
Learn more: https://clinicaltrials.gov/study/NCT05397639
Bristol Meyers Squibb BMS-CN008-0003
The study is designed to evaluate the safety and efficacy of the medication BMS-986446 in
the treatment of early Alzheimer’s Disease (AD) in people 50-80 years of age. This
medication is aimed at one of the toxic proteins involved in the disease process of AD and
has the potential to both prevent the spread of this protein in the brain and promote its
removal. It is theorized that, through these actions, BMS-986446 may be able to slow
disease progression and combat the cognitive decline in patients with early AD. Eligible
patients will receive either one of two doses of the study medication or placebo, which will
be administered by IV infusion every 4 weeks throughout the 76-week treatment period.
The maximum duration of the study is 95 weeks, which also includes a screening period
and a safety follow-up.
Learn more: https://clinicaltrials.gov/study/NCT06268886
Karuna KAR-031
This study is designed to evaluate the safety and efficacy of KarXT for the treatment of
psychosis associated with Alzheimer’s Disease (AD) in people 55-90 years of age. KarXT is
an oral medication that combines two different drugs, one that works on receptors in the
brain to promote antipsychotic activity, and another that works to reduce potential side
effects of the first medication. This combination of medications was found to be well
tolerated and effective in reducing symptoms of psychosis in patients with Schizophrenia,
suggesting it may similarly benefit those suffering from psychosis due to AD. The study
consists of two separate treatment periods, the first of which is 12 weeks long where all
patients will receive the study medication. At the end of these 12 weeks, patients will be
assessed for response to the medication, and those with a positive response will be
randomized to receive either KarXT or placebo for an additional 26 weeks. Those who do
not meet the response criteria at 12 weeks will continue to receive KarXT, as previously
administered, for the remaining 26 weeks. The total treatment duration will be 38 weeks,
along with a screening period and safety follow-up.
Learn more: https://clinicaltrials.gov/study/NCT05511363
Acadia ACP-204-006/ACP-204-008
This study is designed to assess the safety and efficacy of ACP-204 in adults age 55 to 95
who experience hallucinations and delusions associated with Alzheimer’s Disease
psychosis. This medication acts on a specific serotonin receptor in the brain to reverse its
normal effects, which is thought to reduce psychotic symptoms associated with several
conditions, including Alzheimer’s Disease psychosis. The ACP-204-006 study consists of a
6-week treatment period, during which eligible patients will receive one of two different
doses of the study medication or placebo and will take their assigned medication by mouth
once a day for the duration of the six weeks. At the end of this initial treatment period,
patients who continue to meet eligibility criteria will have the option to enroll in the Open
Label Extension study ACP-204-008, where they are guaranteed to receive the study
medication for up to an additional 52 weeks.
Learn more: https://classic.clinicaltrials.gov/ct2/show/NCT06159673
All studies and study related procedures come at no cost to you. There may be some compensation to you for travel and time. Participation is completely voluntary, and you may withdraw at any time. If you would like to know more about our studies, please fill out the form below or give us a call at 203-914-1903.